Bicara Therapeutics Common Stock Overview

Bicara Therapeutics Common Stock Selling, General & Admin

Selling, General & Admin expenses for BCAX.

Quarterly SG&A Expenses

$12.74M

↑ 70.92% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$35.80M

↑ 58.4% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin